These findings collectively suggest that H. pylori infection fosters a tumor microenvironment conducive to immunotherapeutic efficacy, and potential biomarkers such as PD-1/PD-L1 (PDCD1/CD274) expression levels and proliferation/stroma-associated signatures may help guide treatment strategies in this patient population. This evidence concerns the gene CD274 and neoplasm.